LGND:NASDAQ
Ligand Pharmaceuticals
287,39 US$
arrow_downward
-1,14%(-3,32) 1 d
287,39 US$
0,00% (0,00)
bedtimeFuera de horario
Cerrado: 20 ago, 16:00:01 GMT-4 · USD
search
Todos los símbolos
1 d
5 d
1 m
6 m
YTD
1 a
5 a
MÁX.
| Símbolo | Precio | Cambio | % de cambio |
|---|
insights_autoGenerando estadísticas principales de LGND...
Abrir
289,11 US$
Alto
293,37 US$
Bajo
284,87 US$
Cap. burs.
5724,76 M
Vol. medio
297,38 mil
Volumen
138,94 mil
Ratio PER
30,57
Máximo en 52 sem.
326,63 US$
Mínimo en 52 sem.
154,91 US$
BPA
9,40 US$
Beta
1,05
Acciones en circulación
19,94 M
N.º de empleados
47
Abrir
289,11 US$
Alto
293,37 US$
Bajo
284,87 US$
Cap. burs.
5724,76 M
Vol. medio
297,38 mil
Volumen
138,94 mil
Ratio PER
30,57
Máximo en 52 sem.
326,63 US$
Mínimo en 52 sem.
154,91 US$
BPA
9,40 US$
Beta
1,05
Acciones en circulación
19,94 M
N.º de empleados
47
Noticias
De fuentes web y partners de noticias
Vinanet
·
hace 2 días
Ligand (LGND) Latest Results Brief: EPS Exceeds Its Estimate on the Day; Price Action: The Stock Ends Down 1.27% in Latest Trading - Earnings Call Highlights
TipRanks
·
hace 2 días
Ligand Pharmaceuticals Earnings Call Signals Royalty-Driven Surge
Perfil
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
Acerca de Ligand Pharmaceuticals
El contenido generado por IA puede contener errores. Más información